Australia - English - Department of Health (Therapeutic Goods Administration)

strides pharma science pty ltd - ceftazidime pentahydrate, quantity: 1175 mg (equivalent: ceftazidime, qty 1000 mg) - injection, powder for - excipient ingredients: sodium carbonate - auro-ceftazidime is indicated for the treatment of single and mixed infections caused by susceptible aerobic organisms with suspected or documented resistance to other antimicrobials, but not to ceftazidime; as an alternative to aminoglycosides in pseudomonal infection in patients in whom aminoglycoside toxicity is a cause for concern and other antipseudomonal antibiotics cannot be used. . indications include the following.. severe infections in general. for example: septicaemia (including neonatal sepsis), bacteraemia; in patients in intensive care units with specific problems, e.g. infected burns.. respiratory tract. for example: pneumonia, bronchopneumonia, infected pleurisy, infected bronchiectasis and bronchitis.. severe ear, nose and throat infections. for example: otitis media, mastoiditis.. urinary tract. for example: acute and chronic pyelonephritis, pyelitis, cystitis, urethritis (bacterial only); infections associated with bladder and renal stones.. skin and soft tissue. . for example: erysipelas, abscesses, cellulitis, infected burns and wounds, mastitis.. gastrointestinal and abdominal. . for example: intra-abdominal abscesses, enterocolitis.. bone and joint. . for example: osteitis, osteomyelitis, septic arthritis, infected bursitis.

Malaysia - English - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

medispec (m) sdn.bhd - ceftazidime pentahydrate -

Malaysia - English - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

medispec (m) sdn.bhd - ceftazidime pentahydrate -

United States - English - NLM (National Library of Medicine)

b. braun medical inc. - ceftazidime (unii: 9m416z9qnr) (ceftazidime anhydrous - unii:dzr1ent301) - ceftazidime anhydrous 1 g in 50 ml - ceftazidime for injection and dextrose injection is indicated for the treatment of lower respiratory tract infections, including pneumonia, caused by pseudomonas aeruginosa and other pseudomonas spp.; haemophilus influenzae , including ampicillin-resistant isolates; klebsiella spp.; enterobacter spp.; proteus mirabilis ; escherichia coli ; serratia spp.; citrobacter spp.; streptococcus pneumoniae ; and staphylococcus aureus (methicillin-susceptible isolates). ceftazidime for injection and dextrose injection is indicated for the treatment of skin and skin-­structure infections caused by pseudomonas aeruginosa ; klebsiella spp.; escherichia coli ; proteus spp., including proteus mirabilis and indole-positive proteus ; enterobacter spp.; serratia spp.; staphylococcus aureus (methicillin-susceptible isolates); and streptococcus pyogenes (group a beta-hemolytic streptococci). ceftazidime for injection and dextrose injection is indicated for the treatment of bacterial septicemia caused by pseudomonas

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

wockhardt uk ltd - ceftazidime pentahydrate - powder for solution for injection - 1gram

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

wockhardt uk ltd - ceftazidime pentahydrate - powder for solution for injection - 2gram

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

bowmed ibisqus ltd - ceftazidime pentahydrate - powder for solution for injection - 500mg

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

bowmed ibisqus ltd - ceftazidime pentahydrate - powder for solution for injection - 1gram

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

bowmed ibisqus ltd - ceftazidime pentahydrate - powder for solution for injection - 2gram

Australia - English - Department of Health (Therapeutic Goods Administration)

aspen pharmacare australia pty ltd - ceftazidime pentahydrate, quantity: 2.328 g (equivalent: ceftazidime, qty 2 g) - injection, powder for - excipient ingredients: sodium carbonate - fortum is indicated for the treatment of single and mixed infections caused by susceptible aerobic organisms with suspected or documented resistance to other antimicrobials , but not to ceftazidime, and as an alternative to aminoglycosides in pseudomonal infection in patients in whom aminoglycoside toxicity is a cause for concern and other pseudomonal antibiotics cannot be used. indications include: severe infections in general: for example septicaemia, including neonatal sepsis, bacteraemia, and in patients in intensive care units with specific problems, e.g., infected burns. respiratory tract infections: for example, pneumonia, bronchopneumonia, infected pleurisy, infected bronchiectasis and bronchitis. severe ear, nose and throat infections: for example, otitis media, mastoiditis. urinary tract infections: for example, acute and chronic pyelonephritis, pyelitis, cystitis, urethritis (bacterial only), and infections associated with bladder and renal stones. skin and soft tissue infections: for example, erys